SARCOMA

Following its success in acute myeloid leukemia and other cancers, devimistat is being explored as a treatment option for clear cell sarcoma in a phase 1/2 trial.

Phase 2 data show that tyrosine kinase inhibitors can be combined with chemotherapy to improve outcomes in patients with relapsed or refractory osteosarcoma.

The first patient has been dosed in a trial of FHD-609, a selective protein degrader of bromodomain-containing protein 9, for the treatment of synovial sarcoma.

An orphan drug designation has been granted to the CD40 agonistic monoclonal antibody, sotigalimab, for the treatment of patients with soft tissue sarcoma.

During the 2021 American Society of Clinical Oncology Annual Meeting, multiple trials for targeted treatments were presented for soft tissue sarcoma. Dean Frohlich, PhD, and Brian A. Van Tine, MD, PhD, discuss the the results of some of these presentations, including the Spearhead 1 trial.

The FDA has granted priority review to the New Drug Application for nab-sirolimus for consideration as a treatment for patients with advanced malignant perivascular epithelioid cell tumors.

A phase 3 study has been initiated in order to evaluate the efficacy of the oral MDM2 inhibitor milademetan for the treatment of de-differentiated liposarcoma.

The target number of patients with soft tissue sarcoma lung metastases have been enrolled in the phase 1b/2 study of Annamycin, commencing the recruiting portion of the trial.

New data from the phase 2 SPEARHEAD-1 trial showed that afami-cel can elicit encouraging responses in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.

Progression-free survival and disease control in patients with advanced synovial sarcoma was improved by catequentinib.

Brian Van Tine, MD, PhD, and Fadi Braiteh, MD, discuss unmet needs in the treatment of gastrointestinal stromal tumors (GISTs) and look to the future in terms of the evolving field.

Experts discuss the role of multidisciplinary management for patients with gastrointestinal stromal tumors (GISTs).

Implications for treating patients with gastrointestinal stromal tumors (GISTs) in the later lines of therapy after switching from 1 treatment to another.

Brian Van Tine, MD, PhD, and Fadi Braiteh, MD, discuss the current treatment options that are available for the treatment of gastrointestinal stromal tumor (GIST).

An overview of mutations in gastrointestinal stromal tumor (GIST) and how they can influence treatment selection.

Considerations for gastrointestinal stromal tumor (GIST) sequencing in the adjuvant setting.

Fadi Braiteh, MD, discusses sequencing in patients with resectable and unresectable gastrointestinal stromal tumors (GISTs) and explains the impact on treatment considerations.

Experts in the field of gastrointestinal stromal tumors (GISTs) discuss the role of sequencing therapy in the frontline and later-line settings.

Experts discuss advances in gastrointestinal stromal tumors (GIST) and dive into the evolving landscape and ongoing unmet needs.

The FDA has granted fast track designation to Annamycin for the treatment of soft tissue sarcoma lung metastases, according to a press release from Moleculin Biotech, Inc.

In an interview with Targeted Oncology, Margaret von Mehren, MD, reviews the recent advancements in the GIST treatment landscape. She also explains what’s needed to move the needle further in the future.

The novel combined immunotherapy CRX100 has been dosed in the first patient with refractory solid tumors in a phase 1, open-label, dose-escalation study.

Adjuvant imatinib has demonstrated significant improvement in relapse-free survival over a 2-year period and a mild trend toward long-term improvement in failure-free survival as treatment of patients with high-risk gastrointestinal stromal tumors, according to 9.1-year follow-up results from a randomized phase 3 study.

Men appear to be more likely than women to have invasive gastrointestinal stromal tumors originating in the stomach and small intestines. For treatment, an expert says that combined surgery and systemic therapy demonstrates the best outcomes.

In early 2020, the treatment paradigm of soft tissue sarcoma had 3 notable advancements with the FDA approving therapies in epithelioid sarcoma, Kaposi sarcoma, and gastrointestinal stromal tumors.